These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11743514

  • 21. Pulmonary manifestations in young Gaucher disease patients: Phenotype-genotype correlation and radiological findings.
    Gawad Tantawy AA, Moneam Adly AA, Madkour SS, Salah El-Din NY.
    Pediatr Pulmonol; 2020 Feb; 55(2):441-448. PubMed ID: 31774256
    [Abstract] [Full Text] [Related]

  • 22. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 23. [Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months].
    Versteegh C, Avni F, Cuvelier P, Ferster A.
    Arch Pediatr; 1998 Dec; 5(12):1341-3. PubMed ID: 9885741
    [Abstract] [Full Text] [Related]

  • 24. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D, Gelincik A, Canbaz B, Colakoğlu B, Büyüköztürk S, Tanakol R.
    Int Arch Allergy Immunol; 2013 Dec; 160(2):215-7. PubMed ID: 23018845
    [Abstract] [Full Text] [Related]

  • 25. Short-term withdrawal from imiglucerase: what can we learn from it?
    Hollak CE.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):105-6. PubMed ID: 20684887
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 15; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 28. Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.
    Boiret-Dupré N, Descamps S, Coudoré MA, Rapatel C, Kuentz M, Pereira S, Tournadre J, Berger J, Morell P, Berger MG.
    Clin Ther; 2009 Dec 15; 31(12):2900-4. PubMed ID: 20110029
    [Abstract] [Full Text] [Related]

  • 29. Pulmonary hemorrhage in type 3 Gaucher disease: a case report.
    Vellodi A, Ashworth M, Finnegan N, Wallis C.
    J Inherit Metab Dis; 2010 Dec 15; 33 Suppl 3():S329-31. PubMed ID: 20689991
    [Abstract] [Full Text] [Related]

  • 30. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk.
    Sekijima Y, Ohashi T, Ohira S, Kosho T, Fukushima Y.
    Clin Ther; 2010 Nov 15; 32(12):2048-52. PubMed ID: 21118740
    [Abstract] [Full Text] [Related]

  • 31. Echocardiographic assessment in children with Gaucher disease receiving enzyme replacement therapy.
    Ayyıldız ZA, Alehan D, Uslu N, Yüce A, Gürakan F.
    Anadolu Kardiyol Derg; 2012 Mar 15; 12(2):191-2. PubMed ID: 22311875
    [No Abstract] [Full Text] [Related]

  • 32. [Treatment of bone involvement in Gaucher diseases with imiglucerase combined with miglustat].
    Marie I.
    Presse Med; 2009 Dec 15; 38 Suppl 2():2S68-70. PubMed ID: 20304314
    [No Abstract] [Full Text] [Related]

  • 33. Effective desensitization to imiglucerase in a patient with type I Gaucher disease.
    Peroni DG, Pescollderungg L, Piacentini GL, Cassar W, Boner AL.
    J Pediatr; 2009 Dec 15; 155(6):940-1. PubMed ID: 19914435
    [Abstract] [Full Text] [Related]

  • 34. Splenic abscess in a patient with type 3 Gaucher's disease receiving enzyme replacement therapy.
    Maclean K, Wilson MJ.
    J Pediatr; 1999 Feb 15; 134(2):245-7. PubMed ID: 9931539
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy.
    Migita M, Fukunaga Y, Ueda T, Watanabe A, Morita T, Yamamoto M.
    Nihon Ika Daigaku Zasshi; 1994 Nov 15; 61(6):633-7. PubMed ID: 7829657
    [Abstract] [Full Text] [Related]

  • 37. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
    Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S.
    Am J Hematol; 2008 Dec 15; 83(12):890-5. PubMed ID: 18819093
    [Abstract] [Full Text] [Related]

  • 38. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
    Camou F, Viallard JF.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):51-2. PubMed ID: 21983348
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.